Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report issued on Wednesday morning. The brokerage issued a hold rating on the stock.

Other equities research analysts also recently issued reports about the company. HC Wainwright lowered their target price on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. Lake Street Capital cut their target price on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th.

Ekso Bionics Trading Up 4.7 %

Ekso Bionics stock opened at $0.70 on Wednesday. Ekso Bionics has a 52 week low of $0.66 and a 52 week high of $3.13. The stock has a 50-day simple moving average of $0.94 and a 200 day simple moving average of $1.07. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The stock has a market capitalization of $15.29 million, a P/E ratio of -1.07 and a beta of 1.47.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The company had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. During the same quarter in the previous year, the business posted ($0.24) EPS. Analysts expect that Ekso Bionics will post -0.48 earnings per share for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.